Tags : :
The real problem is not the pathogens but the lack of interest from pharmaceutical companies to orphin, rare, tropical diseases. We wont find cures unless some specific companies or research laboratories help us.
A pharmaceutical company has more interest in working with AAR2 drugs against hypertention than against entamoeba or Giardia. They have more interest into creating new NSAID than antiprotozoal drugs.
The solution is only to start a REAL PHARMACEUTICAL COMPANY DEDICATED TO PROTOZOAL, BACTERIAL INFECTIONS where solid researchs are done to get multi answers. And for that, you need no less than 20 millions dollars for a start up.